Donor Selection for Killer Immunoglobulin-like Receptors B Haplotype of the Centromeric Motifs Can Improve the Outcome after HLA-Identical Sibling Hematopoietic Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 1, 2014, Pages 98-105

  Zhou, Huifen ^a   Bao, Xiaojing ^a   Wu, Xiaojin ^a   Tang, Xiaowen ^a   Wang, Miao ^a   Wu, Depei ^a   He, Jun ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Centromeric B; Haplotype; Hematopoietic stem cell transplantation (HSCT); Killer immunoglobulin like receptors (KIR); Sibling

Indexed keywords

BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; HLA A ANTIGEN; HLA ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; METHYLPREDNISOLONE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANCER RADIOTHERAPY; CENTRAL NERVOUS SYSTEM LEUKEMIA; CENTROMERE; CHILD; CHRONIC MYELOID LEUKEMIA; DONOR SELECTION; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HLA SYSTEM; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; SHORT COURSE THERAPY; SIBLING; SURVIVAL; TELOMERE; TRANSPLANTATION RELATED MORTALITY; WHOLE BODY RADIATION; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; DONOR SELECTION; FEMALE; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROGNOSIS; RECEPTORS, KIR; RECURRENCE; RISK; SIBLINGS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84890947569     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.10.017     Document Type: Article

References (33)

1. Lee S.J., Klein J., Haagenson M., et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
2. Cooper M.D., Alder M.N. The evolution of adaptive immune systems. Cell 2006, 124:815-822.
3. Giebel S., Locatelli F., Lamparelli T., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819.
4. Ruggeri L., Capanni M., Urbani E., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
5. Hsu K.C., Keever-Taylor C.A., Wilton A., et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005, 105:4878-4884.
6. Zeis M., Uharek L., Glass B., et al. Allogeneic NK cells as potent anti-leukemic effector cells after allogeneic bone marrow transplantation in mice. Transplantation 1995, 59:1734-1736.
7. Tanaka J., Tutumi Y., Mori A., et al. Sequential analysis of HLA-C specific killer cell inhibitory receptor (CD158b) expressing peripheral blood mononuclear cells during chronic graft-versus-host disease. Bone Marrow Transplant 2000, 26:287-290.
8. Asai O., Longo D.L., Tian Z., et al. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. JClin Invest 1998, 101:1835-1842.
9. Hauch M., Gazzola M.V., Small T., et al. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 1990, 75:2250-2262.
10. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
11. Marsh S.G., Parham P., Dupont B., et al. Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002. Tissue Antigens 2003, 62:79-86.
12. Hsu K.C., Liu X.R., Selvakumar A., et al. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. JImmunol 2002, 169:5118-5129.
13. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
14. Chen D.F., Prasad V.K., Broadwater G., et al. Differential impact of inhibitory and activating Killer Ig-Like Receptors(KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors. Bone Marrow Transplantation 2012, 47:817-823.
15. Symons H.J., Leffell M.S., Rossiter N.D., et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010, 16:533-542.
16. Bao X.J., Hou L.H., Sun A.N., et al. The impact of KIR2DS4 alleles and the expression of KIR in the development of acute GVHD after unrelated allogeneic hematopoietic SCT. Bone Marrow Transplant 2010, 45:1435-1441.
17. Cooley S., Trachtenberg E., Bergemann T.L., et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood 2009, 113:726-732.
18. Cook M.A., Milligan D.W., Fegan C.D., et al. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood 2004, 103:1521-1526.
19. Wongwuttisaroj N., Vejbaesya S., Chongkolwatana V., et al. Analysis of KIR genes in HLA-identical sibling hematopoietic stem cell transplantation in Thai patients with leukemia. JMed Assoc Thai 2012, 95:1261-1265.
20. Dou L.P., Zheng D.H., Wang C., et al. The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people. Int J Hematol 2008, 87:422-433.
21. Sobecks R.M., Ball E.J., Maciejewski J.P., et al. Survival of AML patients receiving HLA-matched sibling donor allogeneic bone marrow transplantation correlates with HLA-Cw ligand groups for killer immunoglobulin-like receptors. Bone Marrow Transplantation 2007, 39:417-424.
22. Kanga U., Mourya M., Seth T., et al. Role of killer immunoglobulin-like receptor-ligand interactions in human leukocyte antigen-matched sibling hematopoietic stem cell transplantation. Transplant Proc 2012, 44:919-921.
23. Littera R., Orru N., Vacca A., et al. The role of killer immunoglobulin-like receptor haplotypes on the outcome of unrelated donor haematopoietic SCT for thalassaemia. Bone Marrow Transplant 2010, 45:1618-1624.
24. Gagne K., Brizard G., Gueglio B., et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002, 63:271-280.
25. Leung W., Iyengar R., Turner V., et al. Determinants of antileukemia effects of allogeneic NK cells. JImmunol 2004, 172:644-650.
26. Pyo C.W., Guethlein L.A., Vu Q., et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Ig-like receptor locus. PLoS One 2010, 5:e15115.
27. Martin A.M., Kulski J.K., Gaudieri S., et al. Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B. Gene 2004, 335:121-131.
28. Farag S., Fehniger T., Ruggeri L., et al. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 2002, 100:1935-1947.
29. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
30. Leung W., Iyengar R., Leimig T., et al. Phenotype and function of human natural killer cells purifi{ligature}ed by using a clinical-scale immunomagnetic method. Cancer Immunology Immunotherapy 2005, 54:389-394.
31. Bishara A., De Santis D., Witt C.C., et al. The benefi{ligature}cial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive Tcells causing GVHD. Tissue Antigens 2004, 63:204-211.
32. Cooley S., Weisdorf D.J., Guethlein L.A., et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010, 116:2411-2419.
33. Fischer J.C., Kobbe G., Enczmann J., et al. The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics 2012, 64:879-885.